Why Aurora Cannabis Inc stock is gaining today

Aurora Cannabis Inc's stock is on the rise, reflecting strong performance in international medical markets.

In the latest trading session, Aurora Cannabis Inc (ACB.TO) saw its stock price increase by 0.48%, closing at CA$4.15. This uptick follows a positive quarterly report that highlighted significant growth in medical cannabis sales, especially outside of Canada.

Investor takeaway: Aurora's shift towards medical cannabis and international markets seems to be paying off, making it a stock to watch for those interested in growth within the cannabis sector.

CA$320.6 million in FY26 net revenue

Aurora Cannabis exceeded revenue expectations with a reported net revenue of CA$320.6 million for FY26, showcasing the effectiveness of its medical-first strategy.

Strong Quarterly Performance

Aurora Cannabis reported a net revenue of CA$320.6 million for FY26, marking an 11% increase year-over-year. This growth was largely driven by an 18% rise in medical cannabis sales, which now make up 91% of the company's total revenue. This strong performance highlights the success of Aurora's strategic pivot towards medical cannabis, particularly in international markets.

Focus on International Markets

With about 55% of its revenue generated outside Canada, Aurora is strategically positioned to leverage the expanding global medical cannabis market. The company’s recent acquisition of Safari Flower Company enhances its capabilities in Europe, addressing both capacity and sourcing risks while tapping into the growing demand in Germany and Poland.

Challenges Ahead

Despite the positive momentum, Aurora faces hurdles, including a projected 30% cut in Canadian reimbursement pricing for medical cannabis. Additionally, the company is intentionally winding down its consumer cannabis segment, which experienced a 55% decline in revenue year-over-year. These factors could pose risks to future profitability and market performance.